$1.10
▼ -2.6% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
Overview
52-week range
$1.18
$3.44
0% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
+1.3%
50% positive
Latest IV / EM
1758%
EM ±415.3% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.05 | — | — | +16.7% | +4.3% | earnings |
| Wed Aug 13, 2025 | Jun/2025 | $-0.04 | — | — | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.06 | — | — | — | -1.8% | earnings |
| Sun Jun 30, 2024 | Jun 2024 | $-0.04 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | — | -$0.04 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 | $0 | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-2M | — | $-2M | $-2M | $-3M | — | $-2M | $-3M |
| Net income | $-2M | — | $-2M | $-2M | $4M | — | $-2M | $-4M |
| EPS (diluted) | — | — | — | $-0.10 | — | — | — | $-0.04 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4M | $8M | $12M | $10M | $7M | $3M | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $14M | $21M | $24M | $26M | $32M | $29M | — | — |
| Total assets | $18M | $26M | $29M | $31M | $37M | $34M | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $49M | $50M | $49M | $49M | $50M | $49M | — | — |
| Total equity | $-34M | $-32M | $-32M | $-30M | $-28M | $-33M | — | — |